TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an advanced clinical stage pipeline of adult stem cell programs.
The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched in different European countries.
TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. The company has initiated a Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, is conducting a Phase IIa trial in rheumatoid arthritis, and successfully concluded a Phase I trial to investigate the potential of intra-lymphatic administration of eASCs for autoimmune disorders.
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect (R) from Tigenix is an autologous chondrocyte treatment for articular cartilage defects of the knee. Defects are debrided, and the defect is sealed with a biological membrane. ChondroCelect is commercially available in Belgium, the Netherlands, Luxembourg, Germany, the...
read full descriptionWhichMedicalDevice is a FREE resource created by clinicians for clinicians.
Registration is free and gives you unlimited access to all of the content and features of this website.
Find out more...Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...
Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.
We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.